Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers

Xiaofu Wang, Lindsey N. Jackson, Sara M. Johnson, Qingding Wang, B. Mark Evers

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Neurotensin, a gut peptide, stimulates the growth of colorectal cancers that possess the high-affinity neurotensin receptor (NTR1). Sodium butyrate (NaBT) is a potent histone deacetylase inhibitor (HDACi) that induces growth arrest, differentiation, and apoptosis of colorectal cancers. Previously, we had shown that NaBT increases nuclear GSK-3β expression and kinase activity; GSK-3β functions as a negative regulator of extracellular signal-regulated kinase (ERK) signaling. The purpose of our current study was to determine: (a) whether HDACi alters NTR1 expression and function, and (b) the role of GSK-3β/ERK in NTR1 regulation. Human colorectal cancers with NTR1 were treated with various HDACi, and NTR1 expression and function were assessed. Treatment with HDACi dramatically decreased endogenous NTR1 mRNA, protein, and promoter activity. Overexpression of GSK-3β decreased NTR1 promoter activity (> 30%); inhibition of GSK-3β increased NTR1 expression in colorectal cancer cells, indicating that GSK-3β is a negative regulator of ERK and NTR1. Consistent with our previous findings, HDACi significantly decreased phosphorylated ERK while increasing GSK-3β. Selective MAP/ERK kinase/ERK inhibitors suppressed NTR1 mRNA expression in a time- and dose-dependent fashion, and reduced NTR1 promoter activity by ∼70%. Finally, pretreatment with NaBT prevented neurotensin-mediated cyclooxygenase-2 and c-myc expression and attenuated neurotensininduced interleukin-8 expression. HDACi suppresses endogenous NTR1 expression and function in colorectal cancer cell lines; this effect is mediated, at least in part, through the GSK-3β/ERK pathway. The downregulation of NTR1 in colorectal cancers may represent an important mechanism for the anticancer effects of HDACi.

Original languageEnglish (US)
Pages (from-to)2389-2398
Number of pages10
JournalMolecular Cancer Therapeutics
Volume9
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Glycogen Synthase Kinase 3
Histone Deacetylase Inhibitors
Extracellular Signal-Regulated MAP Kinases
Colorectal Neoplasms
Neurotensin
Phosphotransferases
Neurotensin Receptors
Messenger RNA
Butyric Acid
neurotensin type 1 receptor
Cyclooxygenase 2
Growth
Interleukin-8
Down-Regulation
Apoptosis
Cell Line
Peptides

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers. / Wang, Xiaofu; Jackson, Lindsey N.; Johnson, Sara M.; Wang, Qingding; Evers, B. Mark.

In: Molecular Cancer Therapeutics, Vol. 9, No. 8, 01.08.2010, p. 2389-2398.

Research output: Contribution to journalArticle

@article{fc2703a4fd5f4a85a9a4a558aac7a5bf,
title = "Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers",
abstract = "Neurotensin, a gut peptide, stimulates the growth of colorectal cancers that possess the high-affinity neurotensin receptor (NTR1). Sodium butyrate (NaBT) is a potent histone deacetylase inhibitor (HDACi) that induces growth arrest, differentiation, and apoptosis of colorectal cancers. Previously, we had shown that NaBT increases nuclear GSK-3β expression and kinase activity; GSK-3β functions as a negative regulator of extracellular signal-regulated kinase (ERK) signaling. The purpose of our current study was to determine: (a) whether HDACi alters NTR1 expression and function, and (b) the role of GSK-3β/ERK in NTR1 regulation. Human colorectal cancers with NTR1 were treated with various HDACi, and NTR1 expression and function were assessed. Treatment with HDACi dramatically decreased endogenous NTR1 mRNA, protein, and promoter activity. Overexpression of GSK-3β decreased NTR1 promoter activity (> 30{\%}); inhibition of GSK-3β increased NTR1 expression in colorectal cancer cells, indicating that GSK-3β is a negative regulator of ERK and NTR1. Consistent with our previous findings, HDACi significantly decreased phosphorylated ERK while increasing GSK-3β. Selective MAP/ERK kinase/ERK inhibitors suppressed NTR1 mRNA expression in a time- and dose-dependent fashion, and reduced NTR1 promoter activity by ∼70{\%}. Finally, pretreatment with NaBT prevented neurotensin-mediated cyclooxygenase-2 and c-myc expression and attenuated neurotensininduced interleukin-8 expression. HDACi suppresses endogenous NTR1 expression and function in colorectal cancer cell lines; this effect is mediated, at least in part, through the GSK-3β/ERK pathway. The downregulation of NTR1 in colorectal cancers may represent an important mechanism for the anticancer effects of HDACi.",
author = "Xiaofu Wang and Jackson, {Lindsey N.} and Johnson, {Sara M.} and Qingding Wang and Evers, {B. Mark}",
year = "2010",
month = "8",
day = "1",
doi = "10.1158/1535-7163.MCT-09-1080",
language = "English (US)",
volume = "9",
pages = "2389--2398",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers

AU - Wang, Xiaofu

AU - Jackson, Lindsey N.

AU - Johnson, Sara M.

AU - Wang, Qingding

AU - Evers, B. Mark

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Neurotensin, a gut peptide, stimulates the growth of colorectal cancers that possess the high-affinity neurotensin receptor (NTR1). Sodium butyrate (NaBT) is a potent histone deacetylase inhibitor (HDACi) that induces growth arrest, differentiation, and apoptosis of colorectal cancers. Previously, we had shown that NaBT increases nuclear GSK-3β expression and kinase activity; GSK-3β functions as a negative regulator of extracellular signal-regulated kinase (ERK) signaling. The purpose of our current study was to determine: (a) whether HDACi alters NTR1 expression and function, and (b) the role of GSK-3β/ERK in NTR1 regulation. Human colorectal cancers with NTR1 were treated with various HDACi, and NTR1 expression and function were assessed. Treatment with HDACi dramatically decreased endogenous NTR1 mRNA, protein, and promoter activity. Overexpression of GSK-3β decreased NTR1 promoter activity (> 30%); inhibition of GSK-3β increased NTR1 expression in colorectal cancer cells, indicating that GSK-3β is a negative regulator of ERK and NTR1. Consistent with our previous findings, HDACi significantly decreased phosphorylated ERK while increasing GSK-3β. Selective MAP/ERK kinase/ERK inhibitors suppressed NTR1 mRNA expression in a time- and dose-dependent fashion, and reduced NTR1 promoter activity by ∼70%. Finally, pretreatment with NaBT prevented neurotensin-mediated cyclooxygenase-2 and c-myc expression and attenuated neurotensininduced interleukin-8 expression. HDACi suppresses endogenous NTR1 expression and function in colorectal cancer cell lines; this effect is mediated, at least in part, through the GSK-3β/ERK pathway. The downregulation of NTR1 in colorectal cancers may represent an important mechanism for the anticancer effects of HDACi.

AB - Neurotensin, a gut peptide, stimulates the growth of colorectal cancers that possess the high-affinity neurotensin receptor (NTR1). Sodium butyrate (NaBT) is a potent histone deacetylase inhibitor (HDACi) that induces growth arrest, differentiation, and apoptosis of colorectal cancers. Previously, we had shown that NaBT increases nuclear GSK-3β expression and kinase activity; GSK-3β functions as a negative regulator of extracellular signal-regulated kinase (ERK) signaling. The purpose of our current study was to determine: (a) whether HDACi alters NTR1 expression and function, and (b) the role of GSK-3β/ERK in NTR1 regulation. Human colorectal cancers with NTR1 were treated with various HDACi, and NTR1 expression and function were assessed. Treatment with HDACi dramatically decreased endogenous NTR1 mRNA, protein, and promoter activity. Overexpression of GSK-3β decreased NTR1 promoter activity (> 30%); inhibition of GSK-3β increased NTR1 expression in colorectal cancer cells, indicating that GSK-3β is a negative regulator of ERK and NTR1. Consistent with our previous findings, HDACi significantly decreased phosphorylated ERK while increasing GSK-3β. Selective MAP/ERK kinase/ERK inhibitors suppressed NTR1 mRNA expression in a time- and dose-dependent fashion, and reduced NTR1 promoter activity by ∼70%. Finally, pretreatment with NaBT prevented neurotensin-mediated cyclooxygenase-2 and c-myc expression and attenuated neurotensininduced interleukin-8 expression. HDACi suppresses endogenous NTR1 expression and function in colorectal cancer cell lines; this effect is mediated, at least in part, through the GSK-3β/ERK pathway. The downregulation of NTR1 in colorectal cancers may represent an important mechanism for the anticancer effects of HDACi.

UR - http://www.scopus.com/inward/record.url?scp=77955498516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955498516&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-1080

DO - 10.1158/1535-7163.MCT-09-1080

M3 - Article

C2 - 20663927

AN - SCOPUS:77955498516

VL - 9

SP - 2389

EP - 2398

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -